Ned Tijdschr Geneeskd. 1998 Apr 18;142(16):912-4.
Recently, the Dutch Working Group on Malaria Prophylaxis produced new national guidelines. The new approach takes the risk of malaria and of serious morbidity or mortality for the individual traveller as its point of departure. In large areas in the tropics, there is no malaria risk. In some areas with limited risk, proguanil is still an effective chemoprophylactic (mainly in Central America, the Near East, Central Asia and parts of Indonesia). However, multiple-drug resistant Plasmodium falciparum necessitates the use of mefloquine, despite disturbing side effects in some people, in Sub-Saharan Africa, major parts of South East Asia and the Amazone basin of South America. If mefloquine is contraindicated, alternatives advised are the combination of proguanil and chloroquine or (in South East Asia) doxycycline. For visits to transmission areas lasting 7 days or less, alternative prophylactic measures may be acceptable, but only if the traveller after the visit has easy access to adequate medical facilities. When exposure lasts not more than two nights, use of a mosquito net, repellents and protective clothing without chemoprophylaxis is acceptable, provided the traveller is well informed. To take along pocket treatment is only advised for some journeys lasting more than one month to areas with multiple-drug resistant falciparum malaria. When mefloquine prophylaxis is used, such stand-by treatment is only advocated for a few countries in South East Asia; when mefloquine cannot be given, also for other areas. The type of pocket treatment recommended depends on the chemoprophylaxis used and on whether contraindications exist. Drugs that can be used are: halofantrine (if no contraindications exist and an ECG shows no prolongation of the QT interval) or quinine, either alone (in pregnancy) or combined with doxycycline or clindamycine (the latter for children < 8 years). With the new individual approach advice may differ for different persons visiting similar tropical areas. It is the physician's task to explain the risks of a particular journey and the measures advised.
最近,荷兰疟疾预防工作组制定了新的国家指南。新方法以个体旅行者感染疟疾以及出现严重发病或死亡的风险为出发点。在热带地区的大片区域,不存在疟疾风险。在一些风险有限的地区,氯胍仍是一种有效的化学预防药物(主要在中美洲、近东、中亚和印度尼西亚部分地区)。然而,由于恶性疟原虫对多种药物耐药,在撒哈拉以南非洲、东南亚大部分地区以及南美洲的亚马逊流域,尽管某些人会出现令人不安的副作用,但仍有必要使用甲氟喹。如果甲氟喹禁忌使用,建议的替代药物是氯胍与氯喹的组合,或者(在东南亚)强力霉素。对于前往传播地区持续7天或更短时间的旅行,替代预防措施可能是可以接受的,但前提是旅行者在旅行结束后能够方便地获得足够的医疗设施。当暴露时间不超过两晚时,在旅行者充分了解情况的前提下,不进行化学预防而使用蚊帐、驱虫剂和防护服是可以接受的。仅建议一些前往耐多药恶性疟疟疾地区且行程超过一个月的旅行携带备用治疗药物。当使用甲氟喹预防时,仅在东南亚的少数国家提倡这种备用治疗;当不能使用甲氟喹时,在其他地区也提倡。推荐的备用治疗药物类型取决于所使用的化学预防药物以及是否存在禁忌证。可以使用的药物有:卤泛群(如果不存在禁忌证且心电图显示QT间期无延长)或奎宁,奎宁可单独使用(用于孕妇)或与强力霉素或克林霉素联合使用(后者用于8岁以下儿童)。采用新的个体化方法时,对于前往类似热带地区的不同人员,建议可能会有所不同。解释特定旅行的风险和建议措施是医生的任务。